The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
28
No.
03
January 18, 2002
- Roswell Park’s Future “Bright” As Center Snares Leading Scientists, Hohn Says.
- ACS Finds 1 In 4 US Deaths From Cancer; Weiss Named NCI Centers Branch Chief.
- Vanderbilt Recruits Sosman To Lead Tumor Immunology.
- Two Court Rulings Conflict In Paclitaxel Patent Battle.
- Smoking Declines Among U.S. Teens, HHS Survey Finds.
TCL
Vol.
28
No.
04
January 25, 2002
- Congressional Committee, SEC Probe ImClone’s Statements To Shareholders.
- Venter Steps Down As Celera President; Moffitt, Puerto Rico Center Win NCI P20 Grant.
- Susan Sieber, Former NCI Communications Chief, Dead.
- Andrew von Eschenbach Sworn In As NCI Director.
- Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.
- Amgen Agrees To Buy Immunex For $16 Billion In Stock And Cash.
- FDA Approves Abbott’s HER-2 DNA Probe Kit.
- Univ. Of Pittsburgh Plans Molecular Medicine Institute.
TCL
Vol.
28
No.
05
February 01, 2002
- Bush Proposes 16 Percent Increase For NIH, To Complete Budget Doubling.
- Ad Council, ACS Begin Ad Campaign To Promote Colon Cancer Screening.
- Biology Societies Endorse Cloning Prohibition Act.
- FASEB Seeks $27.3B For NIH, Increases For Research, Training, And Infrastructure.
- Ivax Paclitaxel To Remain On Market In Deal With BMS.
- Shared Specimen Resource Needed, GYN Review Finds.
TCL
Vol.
28
No.
06
February 08, 2002
- Von Eschenbach Takes NCI’s Helm As Bush Proposes Budget Increase.
- Jerome Yates Named VP For Research At ACS
- MSKCC Wins Zoning Request For New Labs.
- O’Leary Leads RPCI’s OR;
- Brooks Wins ACS Award. NCI Would Get $4.725 Billion, 12% Increase, In Bush Budget.
- BMS Demands Resignation Of Two ImClone Executives
- HHS Reports Some Gains In Reducing Health Disparities
TCL
Vol.
28
No.
07
February 15, 2002
- Expert Review Of ImClone Protocol Concludes C225 Approval Unlikely.
- Retrospective Data Clean-Up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”.
- ImClone Protocol Generates More Questions Than Answers.
- Phase III Trial Would Give Clearer Picture Of C225 Role.
- Thomas Jordan To Help ASCO Enhance International Relations, Retires From BMS.
- Levine Leaves Presidency Of Rockefeller University.
